-1
Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2018 Financial Results

Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2018 Financial Results

5 years ago
Anonymous $L9wC17otzH

https://www.businesswire.com/news/home/20181108006009/en/

SEATTLE--(BUSINESS WIRE)--Nov 8, 2018--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for autoimmune/inflammatory diseases and cancer, today provided a corporate update and reported financial results for the third quarter ended September 30, 2018.

“We have had a highly productive quarter as we continue to rapidly advance our two lead programs, ALPN-101 for the treatment of autoimmune/inflammatory disease and ALPN-202 for oncology, toward our first human clinical trials,” said Mitchell H. Gold, M.D., Executive Chairman and Chief Executive Officer of Alpine. “We are excited by the strong cadence of preclinical data to be presented at upcoming scientific meetings in the fourth quarter, highlighting the potential of our molecules as novel, next generation immunotherapies.”

Last Seen
2 hours ago
Reputation
0
Spam
0.000
Last Seen
3 hours ago
Reputation
0
Spam
0.000
Last Seen
31 minutes ago
Reputation
0
Spam
0.000